While neither liraglutide nor semaglutide is FDA-approved for cardiovascular protection, research suggests both may help lower the risk of major heart-related events like heart attack, stroke, or cardiovascular death in people with type 2 diabetes
nothing here is medical advice
demonstrated, in addition to higher weight loss in the group treated with high-dose liraglutide 3.0 mg/day for 32 weeks, significant improvements not only of fasting glucose and HOMA-IR, but also of the post-load glucose measured by OGTT, OGTT-derived insulin sensitivity index (SIOGTT), and corrected the early insulin response to a glucose challenge (IGI/HOMA) compared to placebo [62]
5 For someone living with established cardiovascular disease, this is a real difference between the two medications
That 14.9% figure became the number to beat